<DOC>
	<DOCNO>NCT02530801</DOCNO>
	<brief_summary>Pterygium common eye disease . Its mechanism remain unknown study suggest relate exposure ultraviolet ray ocular dryness . Pterygium affect vision cause astigmatism may encroach cornea ( transparent part eye ) affect vision . It could cause ocular irritation cosmetically unacceptable especially inflame . Recurrence common outcome pterygium excision . Recurrence rate pterygium vary 10 80 % . Recurrence detect first conjunctiva ( skin eye ) , advance cornea . Treating recurrent pterygium cornea get involve avoids repeat surgery , difficult associate scarring . To avoid repeated surgery , activity recurrent pterygium stop progress true recurrence . Several study attribute recurrence pf pterygium increase substance vascular endothelial growth factor ( VEGF ) fibroblast growth factor . Avastin ( Anti-VEGF ) 5 fluorouracil ( 5FU ) ( antimetabolite ) medication suppress formation VEGF fibroblast growth factor . Studies show subconjunctival injection 5 F Avastin recur pterygium safe effective treatment recurrent pterygium . In many case , vascularization inflammation control subconjunctival Avastin , provide evidence role VEGF pterygium formation . 5FU widely use ophthalmology anti-scarring property . The option treatment recurrent pterygium surgery . Recurrent pterygium challenge condition usually resist conventional surgery rate recurrence surgery high . Moreover , recurrent pterygium surgery usually accompany scarring , risk intra post- complication This study aim generate data inform study towards establish Avastin 5 fluouracil treatment modality recurrent pterygium .</brief_summary>
	<brief_title>Strategies Management Recurrent Pterygium</brief_title>
	<detailed_description>Purpose To assess efficacy combine 5FU Avastin injection treatment recurrent pterygium . Design Pilot study . The patient receive combine 5FU Avastin injection . Methodology Patients inclusion study identify specialist corneal clinic Queens Medical Centre . 5 FU injection Dose : 0.15 ml 5FU ( 3.75mg ) administer body recur pterygium 5 injection determine response . The 5FU solution prepare locally pharmacy ophthalmic use . It deliver preloaded 1ml syringe contain 0.3 ml 2.5mg 5FU per 0.1ml . The injection give topical anaesthesia . One two drop 5 % povidone iodine instill conjunctival sac 5min injection . All injection give outpatient clinic use slit lamp . The needle ( 27Gauge ) advance zigzag manner subconjunctival space , avoid large blood vessel , middle lesion reach . The solution inject needle withdrawn . After injection , 1-2 drop chloramphenicol 0.5 % preservative free minim instill topically continue four time day 3 day injection . Injections carry every two week describe . Patients ability access 24 hour call emergency eye service , time provide contact number investigator query study period . Avastin injection Dose : 0.15 ml Avastin ( 2.5 mg/0.1 ml ) administer body recurrent lesion . Up 5 injection could give . The injection give topical anaesthesia . One two drop 5 % povidone iodine instill conjunctival sac 5min injection . All injection give outpatient clinic use slit lamp . The needle ( 27Gauge ) advance zigzag manner subconjunctival space , avoid large blood vessel , middle lesion reach . The solution inject needle withdrawn . After injection , 1-2 drop chloramphenicol 0.5 % preservativefree minim instill topically continue four time day 3 day injection . Injections carry every two week describe . Patients ability access 24 hour call emergency eye service , time provide contact number investigator query study period . Fluorescein angiography ( FFA ) do characterise conjunctival vessel . It safe routine investigation do daily basis eye clinic . Patient Inclusion Criteria : - Patients age 18 - Able give inform consent - Patients recurrent pterygium within 6 month original excision [ Recurrence define protocol ( page 22 ) ] - Use effective contraception female childbearing age Patient exclusion criterion : - Patients 18 year age - Patients unable refuse provide inform consent - Patients needle phobic - Pregnant woman , woman aim conception breast feeding woman . - Patients hypersensitivity active substance excipients - Patients active suspect ocular periocular infection . - Patients active severe intraocular inflammation . - Patients raise intraocular pressure glaucoma medication - Patients advanced recurrent pterygium extend pupil limbus time presentation In case bilateral eye involvement , one eye treat study drug . The study participant reserve right withdraw study stage , keep date new information available study medication .</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients age 18 Patients able give inform consent Patients early recurrent pterygium within 6 month original excision ( conjunctival recurrence recurrence extend across limbus ) . Use effective contraception female childbearing age . Patients 18 year age Patients unable refuse provide inform consent Patients needle phobic Pregnant woman , woman aim conception breastfeed woman Patients hypersensitivity active substance excipients Patients active suspect ocular periocular infection . Patients active severe intraocular inflammation . Patients raise intraocular pressure glaucoma medication Patients advance recurrent pterygium extend pupil limbus time presentation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>